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The prevalence and risk of missing outcome data in prenatal vitamin D 
supplemented gestational diabetes mellitus patients: a systematic 





Background: Missing outcome data in clinical trials are important determinants of internal validity; however, its burden 
and risk in gestational diabetes mellitus (GDM) mothers supplemented with vitamin D remain poorly studied. 
Therefore, a systematic review and meta-analysis protocol is proposed here to study it.   
Methods: The English language publications, irrespective of its publication date, will be searched in electronic 
databases for randomized controlled trials studying the above outcome. The eligible trials will undergo the risk of bias 
assessment by the Cochrane tool. Data on its trial design, population characteristics, interventions compared, and the 
outcome will be abstracted. The prevalence and incidence (in risk ratio) of missing outcome data will be estimated 
meta-analytically. The statistical heterogeneity assessment will include the use of Chi2 and I2 statistics. For the 
explanation of any substantial heterogeneity, a meta-regression analysis will ensue. The statistical significance will be 
determined at P <0.05 and 95% CI. All analyses will be done in Stata statistical software. If the quantitative analysis is 
not possible, narrative reporting will happen. 
Results: The reporting of the review will follow the PRISMA guideline. Statistically significant pairwise meta-analysis 
finding's grading will occur by the GRADE approach. 
Conclusion: The proposed review will estimate the prevalence of missing outcome data in vitamin D supplemented 
GDM mothers in clinical trials and compare its risk with the placebo recipients.  
PROSPERO registration ID: CRD42020180634 




Gestational diabetes mellitus (GDM) is a medical complication 
of pregnancy. It manifests as glucose intolerance (of any 
degree) that is detected or developed for the first time during 
pregnancy [1]. With the rising trend in obesity and a sedentary 
lifestyle, its prevalence in reproductive age group females is 
increasing globally [2]. GDM’s complications can affect both 
the mother and her neonate. Maternal complications may 
include an increased risk of type 2 diabetes development, 
cesarean section, pre-eclampsia, and polyhydramnios [1,3,4]. 
Some of the fetal complications include newborn 
hypoglycemia, hyperbilirubinemia, and increased perinatal 
mortality [1]. Besides the contemporary GDM management 
practice by dietary modifications, compliance with self-
monitoring of blood glucose levels, and medications [1,5,6], 
novel researches are exploring the role of antenatal vitamin D 
supplementation in the management of GDM and its 
complications. Recently, several trials have studied the effect of 
antenatal vitamin D supplementation in GDM mothers. A meta-
analysis of such trials found that vitamin D supplementation 
might improve certain blood glucose and lipid parameters (e.g., 
homeostatic model assessment for insulin resistance, 
quantitative insulin sensitivity check index, and low-density 
lipoprotein cholesterol) [7]. Other systematic reviews reported a 
reduced risk of cesarean section, macrosomia, neonatal 
hospitalization, and newborn hyperbilirubinemia in vitamin D 
supplemented GDM patients [8,9]. 
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Amidst of these growing numbers of trials testing the effect of 
antenatal vitamin D supplementation in GDM mothers, it is 
crucial to study the validity of its findings due to the missing 
outcome data. Bias due to the latter can also contaminate the 
meta-analysis findings that extract data from these trials [8–10]. 
Notably, attrition is common even in the adequately conducted 
randomized controlled trials (RCT) [11]. In vitamin D 
supplemented trials on GDM patients, both the continuous (e.g., 
gestational weight, body mass index, blood glucose, and lipid 
parameters) and dichotomous (e.g., the frequency of cesarean 
section, pre-eclampsia, preterm delivery, neonatal jaundice, and 
newborn hypoglycemia) outcomes can be affected due to 
missingness of participants from the trials. For continuous 
outcomes, the proportion of missing data determines the risk of 
bias. Among two hypothetical trials with identical observed 
mean and missing values' average, the mean difference of the 
outcomes between the compared intervention groups will be 
higher in the trial with a higher number of participant attrition 
[12]. Whereas, for dichotomous outcomes, comparing the 
missing data to the frequency of events ratio across multiple 
trials helps to juxtapose their risk of bias [12]. 
     Additionally, the causes of missingness between the 
intervention arms also determine the risk of bias in RCTs [12]. 
For instance, in two trials investigating the effects of antenatal 
vitamin D supplementation on GDM patients, the reasons for 
missingness were not identical between the treatment groups 
[13,14]. While intra-uterine fetal demise, placental abruption, 
and hospitalization were the causes of missing outcome data in 
the vitamin D recipients, insulin therapy, pre-eclampsia, 
hospitalization, and placental abruption were the causes in the 
comparison group [13,14]. Along with this, to minimize the risk 
of bias, a balance in attrition frequency between the intervention 
groups of a trial is required [12]. 
     Given these implications of incomplete outcome data, it is 
imperative to investigate its epidemiological burden in antenatal 
vitamin D supplemented GDM mothers and how its risk differs 
from those of placebo recipients. 
 
Intervention description  
Vitamin D is a fat-soluble hormone, available from diet and 
supplements in two inactive forms: D2 (ergocalciferol) and D3 
(cholecalciferol) [15,16]. The D3 form is additionally produced 
in the skin on exposure to the sun [15,16]. Upon hydroxylation 
of pre-vitamin D in the liver, the main circulatory form of 
vitamin D (bound to albumin or in a free state), 25-
hydroxyvitamin D (25(OH)D) is produced [17]. Then, this 
25(OH)D is converted into its active form, calcitriol 
(1,25(OH)2D) [15,18]. Calcitriol stimulates intestinal calcium 
and phosphorus absorption and renal reabsorption of calcium 
via its receptors [16]. It also plays a role in the physiology of 
pregnancy by binding to the vitamin D receptors in the 
uteroplacental tissue [15,18]. The recommended dietary 
allowance and the tolerable upper level of vitamin D intake in 
pregnancy are 600 and 4000IU, respectively [15]. 
     The trials on GDM patients have tested vitamin D 
antenatally in different dosages. As an oral supplement, while 
participants were advised to take 50,000 IU of vitamin D at two 
to three weeks interval for about three to eight weeks in some 
trials [13,14,19,20], other trials recommended 200-500IU of 
vitamin D daily [21,22]. The use of its injectable 
(intramuscular) forms was at a dosage of 300,000 IU [23]. 
Furthermore, while some trials have tested vitamin D as a sole 
prenatal supplement [19,21,23], others have tested it as a co-
supplement with other micronutrients like zinc, calcium, and 
magnesium [14,22]. 
 
Purpose of the proposed review  
Parallel to the rising number of trials testing prenatal vitamin D 
supplementation’s effect in GDM patients, systematic review 
and meta-analysis using data from these trials are also 
increasing. However, best known to this author, the burden and 
risk of attrition in these trials have not been systematically 
explored before [24]. Therefore, to study this poorly explored 
area of the GDM literature, a systematic review protocol is 
proposed here. The proposed review aims to determine the 
pooled weighted prevalence of missing outcome data among 
prenatal vitamin D receiving GDM patients and contrast its risk 
with the placebo recipients. 
 
Methods 
Studies matching the following eligibility criteria will be 
included in the proposed review.  
 
Inclusion criteria 
 1. Study design: Parallel arm (any number of arms) randomized 
controlled trials, irrespective of their blindness and duration. 2. 
Study population: Women of any age diagnosed with GDM 
during their concurrent pregnancy. Women will be recruited 
irrespective of their gravida, parity, or previous history of GDM 
diagnosis. 3. Intervention arm: A trial must test vitamin D as a 
sole or co-supplement with other nutrients in one or more of its 
treatment arms. 4. Comparator arm: The comparator arm should 
receive a placebo. 5. Outcome: Missing outcome data post-
randomization will be the outcome of interest; however, it will 
not form the part of the inclusion criteria. Trialists’ exclusion of 
any available outcome data from the statistical analysis will not 
be considered as missing outcome data. The diagnosis and 
management of GDM and the interventions' dosage, regimen, 
and administration route will be accepted as per the trialists. 
 
Exclusion criteria  
1. Any study design besides the above, like crossover trial or 
quasi-experimental study or observational study. 2. Women 
diagnosed with diabetes of non-GDM variants like diabetes type 
1 or type 2.  
 
Protocol registration   
This review protocol is registered with the PROSPERO 
(CRD42020180634) [25]. This reporting adheres closely to the 
reporting system commended by preferred reporting items for 
systematic review and meta-analysis protocols (PRISMA-P) 
2015 statement [26]. 
 
Database search  
As researchers and participants' safety is concerned, IRB should 
Electronic databases (PubMed, Embase, and Scopus) will be 
searched for the titles and abstracts of the English language 
publications irrespective of its publication date. A draft of the 
search strategy to be used in PubMed is presented here: 
"vitamin D" OR calciferol OR "vitamin D2" OR ergocalciferol 
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OR "vitamin D3" OR cholecalciferol AND "gestational 
diabetes" OR GDM. Subsequent MeSH terms will be used in 
this search "cholecalciferol," "ergocalciferols," and "diabetes, 
gestational." The filters “Clinical Trial” and “Randomized 
Controlled Trial" will be used to narrow down the search results 
to RCTs. Additional searches will be done in the references of 
the reviewed trials. 
 
Study selection  
Citations retrieved from the database searches will be uploaded 
into Rayyan, a systematic review software [27]. Next, the 
duplicate references will be eliminated, and titles and abstracts 
of the remaining articles will be examined for eligible trials. 
Articles seeming to meet these criteria, or for those a decision 
about inclusion or exclusion into the proposed review cannot be 
made by reading these excerpts alone, a full-text reviewing will 
ensue. The last date of the database search, the count of 
citations requiring a full-text reading, and the reason for those 
eliminated after such reading will be maintained. 
 
Data extraction  
Data on the study design, population characteristics, compared 
interventions, and outcome of interest will be abstracted from 
each reviewed trial. In the study design, information on 
randomization, blinding, trial registration number, number of 
intervention arms, single or multi-centeredness, trial duration, 
nation where the trial was conducted, ethical clearance, 
participant consent, and funding information will be extracted. 
Subsequent participant details will be captured from each trial: 
the number of participants randomized to each of the 
intervention arms, their mean age, their diagnosis, and the 
criteria used to make the diagnosis of GDM (e.g., American 
Diabetic Association criteria) [28,29]. The content (e.g., vitamin 
D), dosage, regimen, and mode of administration of each 
intervention arm will be collected. The following details about 
the outcome will be abstracted from each intervention arm - the 
number of participants with missing outcome data and their 
reasons for missingness. 
 
Risk of bias assessment  
The Cochrane tool will be used to assess the selection, 
performance, detection, attrition, reporting, and other bias, and 
each of these biases will be categorized into a low, high, or 
unclear category [12]. The selection bias will be determined by 
the random sequence generation and its allocation concealment 
method from the participants [12]. To judge the performance 
and detection bias, the blinding mechanism of study personnel 
and participants and outcome assessors will be utilized, 
respectively [12]. The attrition bias evaluation will depend on 
the balance of attrition between the compared treatment arms 
and its reasons [12]. The trial results will be juxtaposed to its 
pre-specified intentions [12]. Other biases not categorizable into 
any of the above types will constitute a miscellaneous bias [12]. 
 
Author role  
The review authors will independently select the eligible trials, 
abstract data, and assess the risk of bias. A third-party help will 




The overall and subgroup wise pooled weighted prevalence of 
missingness will be estimated in prenatal vitamin D 
supplemented GDM patients by the random-effect 
(DerSimonian and Laird) meta-analysis for binomial data using 
the exact binomial confidence interval determination method 
and Freeman-Tukey double arcsine transformation procedure 
for variance stabilization [30]. Subgrouping will be done by 
country and continent of the trial, and type of GDM treatment 
(between conservatively treated and medication treated).  
     The risk of missingness between antenatal vitamin D and 
placebo receiving GDM mothers will be contrasted by pairwise 
meta-analysis. Its modeling will depend on the presence 
(random-effect model using DerSimonian and Laird method) or 
absence (fixed-effect model utilizing the inverse-variance 
method) of clinical heterogeneity. The latter will be determined 
by the variations in the characteristics of the trials, participants, 
intervention providers, outcome assessors, and interventions. 
Trials without missing outcome data in both the contrasted 
treatment groups will not be incorporated in this pairwise meta-
analysis. When this outcome does not occur in one of the trial's 
treatment arms, 0.5 will be added to each cell of the 2x2 table 
for meta-analysis. Trials with a high risk of bias component will 
be excluded from the meta-analysis to minimize bias in the 
summary estimates. The statistical significance will be 
determined at p<0.05 and 95% confidence interval. 
 
Heterogeneity and publication bias  
For both binomial and pairwise meta-analysis, the heterogeneity 
will be assessed by Chi2 (statistically significant at P <0.1) [12] 
and I2 (at values 25, 50, and 75%, the heterogeneity will be 
categorized as low, moderate, and high, respectively) [31] 
statistics, and publication bias will be evaluated visually and 
statistically by funnel plots and Eggers test, respectively. 
Heterogeneity evaluation in the prevalence and pairwise meta-
analysis will occur by meta-regression.   
 
Sensitivity analysis  
The meta-analyses will be repeated while eliminating a trial 
each time to evaluate the preliminary meta-analysis's 
robustness. Besides, the pairwise meta-analysis will be iterated 
using a model (random-effect or fixed-effect) alternative to that 
used in the primary analysis.  All analyses will be done in Stata 
statistical software, version 16 (StataCorp, College Station, 
Texas, USA). A statistically significant estimate of the pairwise 
meta-analysis will undergo a quality assessment with the 
Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) approach (by GRADE Working Group 
(2004)) [32]. If the quantitative analysis is not possible, 
narrative reporting will follow. The review's reporting will 
adhere to preferred reporting items for systematic reviews and 
meta-analyses guidelines (PRISMA) [33]. 
 
Discussion  
Contemporarily, several trials have tested the effects of 
antenatal vitamin D supplementation on GDM mothers and 
their infants; however, it is not clear if missing outcome data 
threatens these trials' internal validity meta-analyses that 
abstract data from these. Therefore, a systematic review 
protocol is proposed here to determine the prevalence of 
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missing outcome data in vitamin D supplemented GDM 
mothers and compare its risk with placebo recipients.    
The strengths of the proposed review will perhaps be the first 
systematic review and meta-analysis to estimate the 
epidemiologic burden of missingness among vitamin D 
receiving GDM mothers and compare its risk with placebo 
recipients. Besides, the evidence generated from it is likely to 
be rigorous as it will be based on RCTs, the highest level of the 
epidemiologic evidence. Furthermore, the database search's 
non-restrictiveness to any date or geographical boundary will 
perhaps ensure the proposed review. Concerning the 
weaknesses of the prospective review, it is expected to suffer 
from the following limitations. If the trials included in the 
proposed review primarily uses vitamin D with co-supplements, 
extricating vitamin D’s effect from the latter will be difficult. 
Likewise, accepting the GDM treatment as per the trialists may 
cause the recruitment of a substantial number of trials using 
insulin and/or oral hypoglycemics to treat GDM. In such a 
situation, disentangling its effect on the outcome from that of 
vitamin D supplements' might be challenging. Lastly, the 
inclusion of articles published in the English language only will 
decrease the possibility of identifying relevant trials (if any) 
published in any other language. Despite these limitations, this 
review will be one of the preliminary sources of evidence to 
provide knowledge on the epidemiologic burden and risk of 
missing outcome data on trials that tested vitamin D as a 
supplement in GDM mothers and guide future meta-analysts to 
understand the internal validity of these trials better. 
Simultaneously, the evidence might prove useful to future 
trialists in developing novel trials in terms of minimizing 
attrition and retaining internal validity.  
 
Conclusion  
The proposed review will estimate the prevalence of missing 
outcome data in RCTs testing the effects of vitamin D 




GDM: Gestational Diabetes Mellitus; RCT: Randomized 
Controlled Trials; 25(OH)D: 25-hydroxyvitamin D; 
1,25(OH)2D: Calcitriol;  PRISMA-P: Preferred Reporting Items 
for Systematic Review and Meta-Analysis Protocols; GRADE: 
Grading of Recommendations Assessment, Development, and 
Evaluation; PRISMA: Preferred Reporting Items for Systematic 
reviews and Meta-Analyses guidelines; IU: International  Unit 
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